Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that new drugs from Novartis and Daiichi Sankyo will achieve blockbuster status in the drug market to treat hypertension.

The new Pharmacor report "Hypertension" finds that sales of Novartis's Tekturna, the first renin inhibitor that will be used to treat hypertension, will be bolstered if clinical trial data demonstrate that the drug can provide prevention of end-organ damage superior to that of the angiotensin II receptor antagonist drug class. The launch of Tekturna will mark the first introduction of a new class of antihypertensive medication in more than a decade, and the drug will achieve blockbuster status by earning $2.1 billion by 2015.

The report also finds that only about half of treated hypertensive cases are controlled at blood pressure target levels. In order to achieve blood pressure targets, primary care physicians will increasingly prescribe fixed- dose combination therapies, including Novartis's Exforge and Daiichi Sankyo's amlodipine/olmesartan, to treat the disease in the world's major pharmaceutical markets (the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom). As a result, Exforge and amlodipine/olmesartan will both achieve blockbuster status by 2015, earning $3.2 billion and $1.9 billion, respectively.

"Fixed-dose combinations such as Exforge and amlodipine/olmesartan have the potential to reduce side effects and help to lessen the increasing number of pills patients need to take -- two crucial issues in patient compliance with treatment," said Decision Resources analyst Jeremy Goldman, M.D. "As a result, the use of combination therapy to treat hypertension will double from 20% to 40% of patients between 2005 and 2015."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

Contact: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Eli Lilly's Zyprexa Will Remain the Clinical Gold Standard for the Treatment of Schizophrenia Through 2015

View Now